Guardant wins FDA nod for Guardant360 Liquid CDx cancer test

Guardant Health (GH) stock rises after FDA approval of the company's Guardant360 Liquid CDx blood-based cancer test. Read ...
Insider Monkey

Guardant Health, Inc. (GH)’s ctDNA Test Predicts Colon Cancer Recurrence Risk in Stage III Patients

Guardant Health, Inc. (NASDAQ:GH) and research collaborators have unveiled results from the largest study to date on circulating tumor DNA (ctDNA) testing in stage III colon cancer, presented at the ...